首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1524341

精準醫療市場- 應用（診斷[基於基因、生物標記的測試]、治療[抑制劑藥物、單株抗體]）、適應症（腫瘤學、中樞神經系統）、技術（基因組學、生物資訊學）、最終用戶- 全球預測（2024 年- 2032 年）

Precision Medicine Market - Application (Diagnostics [Genetic, Biomarker Based Tests], Therapeutics [Inhibitor Drugs, Monoclonal Antibodies]), Indication (Oncology, CNS), Technology (Genomics, Bioinformatics), End-user - Global Forecast (2024 - 2032)

出版日期: 2024年04月30日 | 出版商:

Global Market Insights Inc. | 英文 234 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在研究機構、製藥公司和醫療保健提供者之間不斷加強的合作夥伴關係的推動下，精準醫療市場規模預計 2024 年至 2032 年間複合年成長率將達到 7.6%。這些努力正在加速針對個人基因圖譜和病史的個人化治療的發展。同時，政府的措施和資金正在支持這些合作，以促進研究突破並擴大創新療法的可及性。

精準醫療強調巨量資料分析和人工智慧的整合，以提高診斷準確性和治療效果，其重要性日益凸顯，這將有利於產業的成長。例如，2023 年 10 月，歐洲個人化醫療夥伴關係在巴倫西亞的一次高級別會議上啟動。該措施旨在推動精準醫療，以促進創新並在整個歐洲衛生系統中整合個人化醫療解決方案。

該行業根據應用、適應症、技術、最終用戶和地區進行細分。

由於擴大採用基因檢測和分子分析以根據患者個體特徵量身定做治療方法，診斷應用領域的精準醫療市場佔有率預計將在 2032 年大幅成長。這些應用程式使醫療保健提供者能夠更早、更準確地診斷疾病，從而改善患者的治療結果。此外，診斷工具與人工智慧和機器學習等先進技術相結合，以增強診斷的預測能力，使臨床醫生能夠預測疾病進展並推薦個人化介入。

在技術方面，隨著醫療保健提供者正在分析大量患者資料以製定個人化治療計劃，巨量資料分析領域的精準醫療行業預計將在 2024 年至 2032 年期間產生可觀的收入。這項技術能夠整合基因組資訊、醫療記錄和生活方式資料，以發現模式和相關性，從而為精確的醫療干預提供資訊。研究人員和臨床醫生也利用巨量資料分析來識別遺傳傾向、預測治療反應並改善疾病管理策略。

由於慢性病盛行率上升以及對個人化癌症治療的需求不斷增加，歐洲精準醫療產業規模到 2032 年可能會顯著成長。精準醫學計畫正在整合基因組資料和分子分析，為個別患者量身定做治療方案，以改善治療結果和患者的生活品質。對新生物標記和治療標靶的持續探索，利用正在進行的研究來開發更精確的診斷工具和標靶治療，將推動區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 已開發地區癌症生物學的進展
  - 擴大精準醫療藥物組合
  - 越來越多採用基因療法
- 產業陷阱與挑戰
  - 精準醫療成本高
  - 嚴格的監理規範
成長潛力分析
管道分析
未來市場趨勢
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按應用分類，2021 - 2032 年

主要趨勢
診斷
- 基因測試
- 基於生物標記的測試
- 深奧的測試
- 其他測試
療法
- 抑制劑藥物
- 單株抗體
- 細胞與基因治療
- 抗病毒和抗逆轉錄病毒藥物
- 其他療法

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
腫瘤學
中樞神經系統疾病
免疫學
呼吸疾病
遺傳性疾病
皮膚病
其他適應症

第 7 章：市場估計與預測：按技術分類，2021 - 2032

主要趨勢
基因組學
生物資訊學
巨量資料分析
生物標記檢測
高通量篩選
其他技術

第 8 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
診斷實驗室
其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abbott Laboratories, Inc.
Abbvie, Inc.
AstraZeneca plc
bioMerieux SA
Bristol-Myers Squibb Company
Cepheid (Danaher Corporation)
Eli Lilly & Company
F. Hoffmann-La Roche
GlaxoSmithKline plc
Laboratory Corporation of America Holdings (Covance Inc.)
Myriad Genetics, Inc.
Novartis AG
Pfizer, Inc.
QIAGEN N.V.
Quest Diagnostics
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vyant Bio, Inc. (Cancer Genetics, Inc.)

簡介目錄

Product Code: 671

Precision Medicine Market size is expected to record 7.6% CAGR between 2024 and 2032, driven by rising partnerships between research institutions, pharmaceutical companies, and healthcare providers. These efforts are accelerating the development of personalized treatments tailored to individual genetic profiles and medical histories. Simultaneously, government initiatives and funding are supporting these collaborations for fostering research breakthroughs and expanding access to innovative therapies.

The surging importance of precision medicine for emphasizing the integration of big data analytics and AI to enhance diagnostic accuracy and treatment outcomes will favor the industry growth. For instance, in October 2023, the European Partnership for personalized medicine was launched in Valencia at a high-level conference. This initiative aimed at advancing precision medicine for fostering innovations and integrating personalized healthcare solutions across European health systems.

The industry is segmented based on application, indication, technology, end-user, and region.

Precision medicine market share from the diagnostics application segment is expected to witness substantial growth through 2032, backed by the rising adoption of genetic testing and molecular profiling to tailor treatments based on individual patient characteristics. These applications are enabling healthcare providers to diagnose diseases earlier and with greater accuracy for improving patient outcomes. In addition, diagnostic tools are incorporated with advanced technologies, such as AI and machine learning to enhance predictive capabilities of diagnostics for enabling clinicians to anticipate disease progression and recommend personalized interventions.

In terms of technology, the precision medicine industry from the big data analytics segment is slated to generate notable revenue during 2024-2032 as healthcare providers are analyzing vast amounts of patient data to personalize treatment plans. This technology is enabling the integration of genomic information, medical records, and lifestyle data to uncover patterns and correlations that inform precise medical interventions. Researchers and clinicians are also harnessing big data analytics to identify genetic predispositions, predict treatment responses, and improve disease management strategies.

Europe precision medicine industry size is likely to record a notable growth rate through 2032 driven by the rising prevalence of chronic diseases and the increasing demand for personalized cancer therapeutics. Precision medicine initiatives are integrating genomic data and molecular profiling to customize therapies for individual patients to improve treatment outcomes and patient quality of life. The growing exploration of new biomarkers and therapeutic targets for leveraging ongoing research to develop more precise diagnostic tools and targeted therapies will drive the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advancements in cancer biology in developed region
  - 3.2.1.2 Expanding portfolio of precision medicine drugs
  - 3.2.1.3 Increasing adoption of gene therapy
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of precision medicine
  - 3.2.2.2 Stringent regulatory norms
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Future market trends
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diagnostics
- 5.2.1 Genetic tests
- 5.2.2 Biomarker based tests
- 5.2.3 Esoteric tests
- 5.2.4 Other tests
5.3 Therapeutics
- 5.3.1 Inhibitor drugs
- 5.3.2 Monoclonal antibodies
- 5.3.3 Cell & gene therapy
- 5.3.4 Antiviral & anti-retroviral drugs
- 5.3.5 Other therapeutics

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oncology
6.3 CNS disorders
6.4 Immunology
6.5 Respiratory diseases
6.6 Genetic disorders
6.7 Skin diseases
6.8 Other indications

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Genomics
7.3 Bioinformatics
7.4 Big data analytics
7.5 Biomarker detection
7.6 High throughput screening
7.7 Other technologies

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Diagnostic laboratories
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa